AstraZeneca To Pay $39B For Alexion — 14% Off Its All-Time High
- Sunday, December 13, 2020, 7:11
- Market
- Add a comment
At $39 billion, AstraZeneca is low-balling its bid for Alexion — maker of Soliris, a drug that sells for $678,302 a year
About the Author
admin123 has written 23544 stories on this site.
